Study Purpose:
ABBV-CLS-7262 is an investigational drug being researched for the treatment of Amyotrophic Lateral Sclerosis. This is a 48-week, 2-part study. Part 1 will be a 4-week, randomized, double-blind, placebo-controlled study; Part 2 will be a 44-week active treatment extension (ATE) during which all subjects will receive ABBV-CLS-7262.Subjects will attend regular visits during the course of the study and complete medical assessments, blood tests, checking for side effects, and completing questionnaires.
Study Status:
Recruiting
Disease:
ALS , Amyotrophic Lateral Sclerosis
Study Type:
Interventional
Type of Intervention:
Drug
Intervention Name:
ABBV-CLS-7262, Placebo
Placebo:
Yes
Phase:
Phase 1
Study Chair(s)/Principal Investigator(s):
N/A
Clinicaltrials.gov ID:
Neals Affiliated?
No
Coordinating Center Contact Information
Calico Call Center / email hidden; JavaScript is required / 1-844-463-2423
Study Sponsor:
Calico Life Sciences LLC
Participant Duration:
48 weeks
Estimated Enrollment:
30
Estimated Study Start Date:
09 / 22 / 2021
Estimated Study Completion Date:
05 / 01 / 2023
Posting Last Modified Date:
06 / 22 / 2022
Date Study Added to neals.org:
07 / 02 / 2021
Minimum Age:
18 Years
Maximum Age:
80 Years
Can participants use Riluzole?
Yes
Inclusion Criteria:- Must have an identified, reliable caregiver
- Confirmed diagnosis of Familial ALS or Sporadic ALS
- First ALS symptoms occurred ≤36 months before screening
- Able to swallow solids
- No known active COVID-19 infection at screening
- Vital capacity ≥50% predicted value (for sex, age, ethnic origin, and height) at screening
- Subjects must be a) naïve to, or b) off riluzole (Rilutek), or c) on a stable dose >30 days prior to Baseline visit to enter study
- Subjects must be a) naïve to, or b) off edaravone (Radicava), or c) have completed 2 treatment cycles prior to the Baseline visit.
Exclusion Criteria:
- History of dementia/severe cognitive problems at screening
- Use of riluzole (Rilutek®) if dose has NOT been stable for > 30 days prior to Baseline visit
- History of clinically significant medical conditions (other than ALS) or any other reason, including any physical, psychological, or psychiatric condition that, in the opinion of the Investigator, would compromise the safety or interfere with the subject's participation in the study, or would make the subject an unsuitable candidate to receive study drug, or would put the subject at risk by participating in the study.
- History of abnormal screening laboratory or imaging results that, in the opinion of the Investigator, are indicative of any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, infectious, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, neurologic, and/or other major disease that would preclude administration of ABBV-CLS-7262.
- If female, is known to be pregnant, breastfeeding, considering becoming pregnant, or donating/banking eggs during the study or within 30 days or >5 half-lives (whichever is longer) after the last dose of study drug
- If male, plans to donate sperm or father a child during the study or within 30 days after the last dose of study drug.
- Known to have received any investigational product within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug or is currently enrolled in another clinical study.
- History of ABBV-CLS-7262 use prior to participation in this study
- Recent (within 6 months prior to Screening) history of drug or alcohol abuse
- Previous participation in a stem cell clinical study
- Current or anticipated use of diaphragmatic pacing during the study period
- Tracheostomy or use of non-invasive ventilatory support ≥22 hours a day
UC Irvine Health ALS and Neuromuscular Center | Recruiting
Principal Investigator : Namita Goyal
Irvine, California
92868
United States
Forbes Norris MDA/ALS Research and Treatment Center | Recruiting
Principal Investigator : Jonathan Katz
San Francisco, California
94109
United States
Mayo Clinic | Recruiting
Principal Investigator : Bjorn Oskarsson
Jacksonville, Florida
32224
United States
Healey & AMG Center for ALS Research | Recruiting
Darshana Hari / 617-643-3530 / email hidden; JavaScript is required
Max Higgins / 617 643-2522 / email hidden; JavaScript is required
Principal Investigator : Doreen Ho
Boston, Massachusetts
02114
United States
Mayo Clinic | Recruiting
Principal Investigator : Nathan Staff
Rochester, Minnesota
55905
United States
University of Calgary - Heritage Medical Research Clinic | Recruiting
Principal Investigator : Rodney Li Pi Shan
Calgary, Alberta
T2V1P9
Canada
University of Alberta | Recruiting
Principal Investigator : Wendy Johnston
Edmonton, Alberta
T6G 2G3
Canada
Stan Cassidy Centre for Rehabilitation | Recruiting
Principal Investigator : Colleen O'Connell
Fredericton, New Brunswick
E38 0C7
Canada
London Health Sciences Centre | Recruiting
Principal Investigator : Christen Shoesmith
London, Ontario
N6A585
Canada
Sunnybrook Research Institute | Recruiting
Principal Investigator : Lorne Zinman
Toronto, Ontario
M4N 3M5
Canada
Centre Hospitalier de l'Universite de Montreal (CHUM) | Recruiting
Principal Investigator : Genevieve Matte
Montreal, Quebec
H2L 4M1
Canada
Montreal Neurological Institute and Hospital | Recruiting
Principal Investigator : Angela Genge
Montreal, Quebec
H3A 2B4
Canada